| Income Statement | 2025-06-30 | 2025-03-31 | ||
|---|---|---|---|---|
| Revenue | 983,518 | 1,364,341 | ||
| Cost of revenue | 397,686 | 420,447 | ||
| Gross profit | 585,832 | 943,894 | ||
| Professional fees | 363,533 | 331,733 | ||
| Advertising and marketing | 147,605 | 157,321 | ||
| Officer compensation | 22,500 | 22,500 | ||
| General and administrative | 207,448 | 245,566 | ||
| Depreciation and amortization expense | 54,832 | 51,814 | ||
| Investor relations | 40,000 | - | ||
| Total operating expenses | 835,918 | 808,934 | ||
| Net loss from operations | -250,086 | 134,960 | ||
| Interest expense | 1,055,371 | 893,850 | ||
| Derivative financial instruments | -328 | -1,149 | ||
| Total other expense | -1,055,699 | -894,999 | ||
| Net loss | -1,305,785 | -760,040 | ||
| Net loss per common share, basic (in dollars per share) | -0.1 | -0.06 | ||
| Net loss per common share, diluted (in dollars per share) | -0.1 | -0.06 | ||
| Weighted average number of common shares outstanding, basic (in shares) | 12,538,968 | 12,538,968 | ||
| Weighted average number of common shares outstanding, diluted (in shares) | 12,538,968 | 12,538,968 | ||
Regenerative Medical Technology Group Inc. (RMTG)
Regenerative Medical Technology Group Inc. (RMTG)